Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The U.S. label does not establish renal pharmacokinetics. UCSF and the handbook provide additional recommendations; these cannot be called matching renal-label protocols.
Check source scope before reading a dose
MEPRON suspension - U.S. label; renal pharmacokinetics not studied
Product / population
Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method
No renal-function dose bands specified for this summary.
Source revision
DailyMed updated 2026-03-20.
Retrieved
2026-09-05
Local review status
Locally included source-specific summary. Regimen differences are not automatically resolved.
Official
MEPRON suspension - U.S. label; renal pharmacokinetics not studied
NIH/NLM DailyMed - U.S. product labeling · Adults; named product and route only. Selected dosing and renal summary, not the full prescribing information.
Renal method: No renal-function dose bands specified for this summary. Source date: DailyMed updated 2026-03-20. Retrieved: 2026-09-05
Locally included source-specific summary. Regimen differences are not automatically resolved.
Dosing / renal protocol and limits
For adults unable to tolerate TMP-SMX, PJP prevention uses 1500 mg (10 mL) orally once daily with food. Mild-to-moderate PJP treatment uses 750 mg (5 mL) twice daily with food for 21 days. The suspension is 750 mg/5 mL. Severe PJP is outside the studied treatment scope.
The label states that pharmacokinetics have not been studied in renal impairment. It does not supply a CrCl-based adjustment or dialysis protocol. The separately displayed UCSF dialysis regimen is therefore institutional guidance, not an FDA-confirmed renal regimen. Review absorption problems, interacting drugs and the March 2026 severe-cutaneous-reaction warning.
RDM30-073-atovaquone-1 · Source locator: MEPRON suspension - U.S. label; renal pharmacokinetics not studied; renal/dosing sections and stated qualifiers
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.